Research Paper Volume 15, Issue 8 pp 3035—3051

Figure 7. Inhibition of TYRO3 expression enhances drug sensitivity of CRC cells in vivo. (A) Weight change of the NC, KD, NC+5-Fu and KD+5-Fu group mice recorded twice a week during the experiment (n = 5). (B) Weight change of the NC, KD, NC+5-Fu and KD+5-Fu group mice on day28 (n = 5). (C) Tumor volume of the NC, KD, NC+5-Fu and KD+5-Fu group mice recorded twice a week during the experiment (n = 5). (D) Tumor volume of the NC, KD, NC+5-Fu and KD+5-Fu group mice on day28 (n = 5). (E) Representative pictures of subcutaneous tumors harvested from NC and TYRO3-KD group treated with 5-Fu or not (the maximum and minimum removed). (F) Tumor weight of the NC, KD, NC+5-Fu and KD+5-Fu group mice (n = 5). (G) The association analysis between weight change of mice and tumor weight in 5-Fu treated group (n = 5). (H) Stratification of mice into different clusters according to weight change and tumor weight in 5-Fu treated group (n = 5). (I) Percentage of NC and TYRO3-KD mice in each cluster. Abbreviations: NC: negative control; KD: TYRO3-shRNA. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001.